Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial

PURPOSE: The JFMC33-0502 trial is a phase III clinical study designed to determine the most appropriate duration of postoperative adjuvant chemotherapy with uracil–tegafur (UFT) plus leucovorin in patients with stage IIB or III colon cancer. We report the interim results of preplanned safety analyse...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuchiya, Takashi, Sadahiro, Sotaro, Sasaki, Kazuaki, Kondo, Ken, Katsumata, Kenji, Nishimura, Genichi, Kakeji, Yoshihiro, Baba, Hideo, Morita, Takayuki, Koda, Keiji, Sato, Seiji, Matsuoka, Junji, Yamaguchi, Yoshiyuki, Usuki, Hisashi, Hamada, Chikuma, Kodaira, Susumu, Saji, Shigetoyo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032639/
https://www.ncbi.nlm.nih.gov/pubmed/24744162
http://dx.doi.org/10.1007/s00280-014-2461-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032639/
https://www.ncbi.nlm.nih.gov/pubmed/24744162
http://dx.doi.org/10.1007/s00280-014-2461-5

Ejemplares similares